HALT PROGRESSION OF POLYCYSTIC KIDNEY DISEASE

阻止多囊肾疾病的进展

• 批准号: 7603623
• 负责人: ARLENE B CHAPMAN
• 金额: $ 4.16万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603623
• 关键词: Antihypertensive Agents; Autosomal Dominant Polycystic Kidney; Blood Pressure; Cessation of life; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Creatinine; End stage renal failure; Funding; Grant; Hypertension; Hypotension; Institution; Kidney; Kidney Failure; Polycystic Kidney Diseases; Renal function; Research; Research Personnel; Resources; Serum; Source; Standards of Weights and Measures; Time; United States National Institutes of Health; Upper arm; blood pressure regulation

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has two arms, the aim in study A is to determine whether ADPKD subjects with preserved renal function (GFR >60 ml/min/1.73m2) and high-normal blood pressure or hypertension, ACE-I/ARB combination therapy and low blood pressure vs ¿-blocker and usual blood pressure reduces the percent increase in kidney volume over time. The aim in study B is to determine whether ADPKD subjects with moderate renal insufficiency (GFR 30-60 ml/min/1.73m2), ACE-I/ARB combination therapy as compared to ACE-I, with additional antihypertensive agents at standard blood pressure control (?130/85 mm Hg), increases the time to doubling of serum creatinine, ESRD or death.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以出现在其他 CRISP 条目中 列出的机构是。 对于中心来说，它不一定是研究者的机构。 本研究有两个组，研究 A 的目的是确定 ADPKD 受试者是否具有保留的肾功能（GFR > 60 ml/min/1.73m2）和正常高值血压或高血压，ACE-I/ARB 联合治疗和低血压血压与 ¿研究B的目的是确定ADPKD受试者是否患有中度肾功能不全（GFR 30-60ml/min/1.73m2），ACE-I/ARB组合是否会随着时间的推移而降低肾体积的百分比增加。与 ACE-I 相比，在标准血压控制 (?130/85 mm Hg) 下使用额外的抗高血压药物，增加了血清肌酐倍增的时间， ESRD 或死亡。